[Action of natural estrogens on the vessel wall: molecular mechanisms and clinical implications].
Myocardial infarction is the major cause of death in the Western world. Men are more prone to develop coronary artery disease than women, who rarely develop coronary disease before menopause. Although epidemiological data has long been available showing a protective effect of estrogen on the vascular system, the underlying mechanisms have been investigated more thoroughly only in recent years. Meta-analysis studies have revealed that only half of the protective effect on estrogen replacement therapy is due to its positive effects on the lipid profile and that a large part of this protection is caused by mechanisms distinct from lipid metabolism. It is now known that estrogens also exert effects on vascular function and structure of the vessel wall involving numerous cellular and molecular mechanisms. Here we review actions of natural estrogens on human vascular cells and arteries. Estrogens can modulate vascular function by increasing nitric oxide production via stimulation of endothelial nitric oxide synthase (eNOS) and decreasing endothelin-1 levels in vivo. Furthermore, 17 beta-estradiol is an inhibitor of vascular smooth muscle cell proliferation and migration, phenomena that play a major role in atherosclerotic vascular disease and in the remodelling process. 17 beta-estradiol can also acutely affect vascular tone in human arteries and attenuates constriction induced by contractile agonists. Finally, clinical studies have shown that 17 beta-estradiol can acutely and chronically ameliorate vascular function in women with and without vascular disease. In conclusion, results from clinical and in vitro studies confirm the positive effects of natural estrogens on vascular function and protection from coronary heart disease. Thus, primary prevention of coronary heart disease by estrogen replacement therapy after the menopause appears to be a new and straightforward approach by which cardiovascular mortality in women can be reduced.
Lüscher
T F
TF
Kardiologie und Kardiovaskuläre Forschung, Inselspital Bern.
Barton
M
M
Wight
E
E
Espinosa
E
E
Yang
Z
Z
D000328:Adult; D000368:Aged; D001161:Arteriosclerosis / Q000503:physiopathology; D003327:Coronary Disease / Q000517:prevention & control; D019332:Endothelin-1 / Q000037:antagonists & inhibitors; D004727:Endothelium / Q000187:drug effects; D004958:Estradiol / Q000494:pharmacology; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009131:Muscle, Smooth, Vascular / Q000187:drug effects* / Q000502:physiology; D019001:Nitric Oxide Synthase / Q000096:biosynthesis / Q000494:pharmacology
D019332:Endothelin-1; D004967:Estrogens; D004958:Estradiol; D019001:Nitric Oxide Synthase
Wirkungen natürlicher Ostrogene auf die Gefässwand: molekulare Mechanismen und klinische Implikationen.